This is a prospective, randomized, double-blind, sham-controlled, multicenter, Phase 3 study
in which eligible subjects with acute otitis externa (AOE) will be randomized to receive a
single administration of either 12 mg OTO-201 or Sham-Control (empty syringe) to the external
auditory canal of the affected ear(s).